Soleno Therapeutics, Inc. Common Stock
SLNO
$52.25
+32.31%
Soleno Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapeutics for the treatment of rare diseases, operating within the biotechnology industry. The company is a clinical-stage entity whose identity is defined by its sole therapeutic product candidate, DCCR (Diazoxide Choline) Extended-Release tablets, a proprietary formulation for a rare genetic disorder. The current investor narrative is dominated by significant legal and commercial uncertainty, as the company faces a securities fraud lawsuit alleging it misled investors about the safety and commercial prospects of DCCR, which has contributed to substantial stock price volatility and a reevaluation of its near-term commercialization pathway.…
SLNO
Soleno Therapeutics, Inc. Common Stock
$52.25
Related headlines
Investment Opinion: Should I buy SLNO Today?
Rating: Hold. The core thesis is that SLNO presents an asymmetric risk/reward profile where compelling fundamentals are overshadowed by an existential legal threat, making the stock uninvestable until the lawsuit clarity emerges.
Supporting evidence includes the company's strong Q4 2025 fundamentals: revenue of $91.73M, net margin of 47.27%, free cash flow of $48.65M, and a debt-free balance sheet. However, these are countered by a trailing PE of 117.86x, a negative forward PE, a 46.4% annual price decline, and a beta of -2.805 indicating extreme, inverse volatility. Analyst revenue estimates of $1.64B for the next year suggest significant growth, but the forward PE of -17.40x implies deep skepticism about earnings sustainability.
The thesis would upgrade to a Buy if the securities lawsuit is resolved favorably without material impact, and quarterly revenue demonstrates sustained growth above $90M with stable margins. It would downgrade to a Sell if revenue growth decelerates sequentially, the legal situation worsens, or the stock breaks below its $29.43 support level. Currently, the stock is fairly valued for the extreme binary risk it carries; it is not clearly overvalued given its growth, nor undervalued given its legal peril.
Sign up to view all
SLNO 12-Month Price Forecast
SLNO is a classic 'show me' story trapped between a rock-solid quarterly report and a potentially catastrophic legal threat. The AI assessment is neutral due to this unresolvable tension. The high confidence stems from the clarity of the data dichotomy: the fundamentals scream 'buy' while the technicals and news flow scream 'sell.' The stance would upgrade to bullish only upon clear legal resolution, as the underlying business metrics are strong. It would turn bearish if the next quarterly report shows revenue deceleration, proving the lawsuit has already damaged commercial prospects. Investors should await clarity on the legal front before establishing a position.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Soleno Therapeutics, Inc. Common Stock's 12-month outlook, with a consensus price target around $67.92 and implied upside of +30.0% versus the current price.
Average Target
$67.92
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$42 - $68
Analyst target range
Insufficient analyst coverage data is available to provide a meaningful consensus on price targets or recommendations. The provided data includes institutional rating actions but lacks the critical components of a full analyst consensus, such as the number of analysts, a consensus rating (e.g., Buy/Hold/Sell), and an average price target. The absence of this data typically indicates the stock is a smaller-cap, clinical/commercial-stage biotech with limited or nascent Wall Street coverage, which can lead to higher volatility and less efficient price discovery as the investment narrative is shaped by a smaller group of institutional investors and company-specific news flow. The available institutional ratings show a pattern of reiterated 'Buy' or 'Overweight' ratings from firms like HC Wainwright, Wells Fargo, and TD Cowen throughout late 2025 and early 2026, even as the stock price fell. However, the most recent news of a securities fraud lawsuit represents a significant new catalyst that may not yet be reflected in these older ratings, suggesting analyst models and targets are likely in flux, contributing to high uncertainty and a wide potential dispersion in future targets.
Bulls vs Bears: SLNO Investment Factors
The evidence presents a stark dichotomy: fundamentally, SLNO has executed a remarkable commercial launch, achieving explosive revenue growth and high-margin profitability with a pristine balance sheet. Technically and sentimentally, the stock is in crisis, crushed by a securities fraud lawsuit and trading near 52-week lows with extreme volatility. Currently, the bearish narrative of legal and commercial uncertainty holds stronger evidence, as it directly threatens the sustainability of the bullish fundamentals. The single most important tension is the resolution of the securities lawsuit versus the continuation of strong commercial execution. If the legal overhang clears, the fundamental strength could drive a powerful re-rating. If the lawsuit validates the bear case, the commercial success story could unravel.
Bullish
- Explosive Revenue Growth & Profitability: Revenue surged from $0 in Q1 2025 to $91.73 million in Q4 2025, demonstrating rapid commercial uptake of its lead drug. This growth translated into a net income of $43.36 million and a net margin of 47.27% in Q4, marking a dramatic shift from deep losses to high profitability in under a year.
- Exceptional Gross & Operating Margins: The company boasts a gross margin of 99.06% and an operating margin of 44.08% for Q4 2025, typical for a commercial-stage biotech with a proprietary drug. These margins provide significant operating leverage and cash generation potential as sales scale.
- Strong Balance Sheet & Cash Flow: The company generated $48.65 million in free cash flow in Q4 2025 and has a robust current ratio of 5.80 with minimal debt (debt-to-equity of 0.006). This strong financial position provides a buffer against operational risks and funds future growth without dilution.
- Analyst Revenue Growth Expectations: Analysts project average revenue of $1.64 billion for the next fiscal year, implying significant growth from the $91.73 million quarterly run-rate. This expectation, if met, could justify a higher valuation multiple on future earnings.
Bearish
- Securities Fraud Lawsuit Overhang: The company faces a securities fraud lawsuit alleging it misled investors about the safety and commercial prospects of its lead drug, DCCR. This legal uncertainty creates a severe overhang on the stock, contributing to its 46.4% annual decline and 66.04% maximum drawdown.
- Extreme Valuation Distortion & Volatility: The stock trades at a trailing PE of 117.86x and a forward PE of -17.40x, indicating severe earnings volatility expectations. Its beta of -2.805 shows it moves inversely and with nearly triple the market's magnitude, making it a highly speculative and unpredictable holding.
- Sole Product Dependency & Legal Risk: The company's entire revenue and future depend on one product, DCCR (VYKAT XR). The ongoing lawsuit directly challenges this product's commercial narrative, creating an existential risk where adverse legal developments could cripple the business model.
- Technical Downtrend & Weak Sentiment: The stock is in a pronounced downtrend, trading at $39.49, which is only 16.5% above its 52-week low of $29.43 and 56% below its 52-week high of $90.32. This positioning near lows reflects overwhelming bearish sentiment and a lack of buyer conviction.
SLNO Technical Analysis
The stock is in a pronounced and sustained downtrend, having declined 46.40% over the past year. With a current price of $39.49 (as of the latest data point on April 2, 2026) and a 52-week range of $29.43 to $90.32, the stock is trading at approximately 16.5% of its 52-week range, positioning it much closer to its 52-week low than its high. This extreme positioning near the lows suggests the stock is in a deep value or 'fallen knife' territory, indicating severe bearish sentiment and potential fundamental distress rather than a simple correction. Recent momentum shows a stark divergence, with the stock up 4.69% over the past month but down 16.28% over the past three months. This positive 1-month move against the powerful longer-term downtrend could signal a potential oversold bounce or mean reversion attempt, but it is occurring amidst a massive 66.04% maximum drawdown, highlighting the extreme volatility and risk inherent in the name. Key technical levels are clearly defined, with immediate support at the 52-week low of $29.43 and formidable resistance at the 52-week high of $90.32. A breakdown below $29.43 would signal a continuation of the bear trend into uncharted territory, while any sustained move above $90.32 seems highly improbable in the near term. The stock exhibits extreme volatility relative to the market, with a beta of -2.805, indicating it has moved inversely and with nearly three times the magnitude of the broader market, which is critical for risk-aware investors considering position sizing.
Beta
-2.81
-2.81x market volatility
Max Drawdown
-66.0%
Largest decline past year
52-Week Range
$29-$90
Price range past year
Annual Return
-22.6%
Cumulative gain past year
| Period | SLNO Return | S&P 500 |
|---|---|---|
| 1m | +31.7% | -2.0% |
| 3m | +13.2% | -4.8% |
| 6m | -16.7% | -2.1% |
| 1y | -22.6% | +30.4% |
| ytd | +10.8% | -3.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SLNO Fundamental Analysis
The company's revenue trajectory has undergone a dramatic and positive inflection, moving from $0 in the first quarter of 2025 to $91.73 million in Q4 2025, representing the initiation of commercial sales for its lead product. This quarterly revenue of $91.73 million marks a significant sequential acceleration from $66.02 million in Q3 2025 and $32.66 million in Q2 2025, demonstrating rapid commercial uptake. The growth is driven entirely by its sole 'Product' segment, which generated $32.66 million in the Q2 period for which segment data is available. Profitability has similarly transformed, with the company reporting a net income of $43.36 million and a robust net margin of 47.27% for Q4 2025, a stark reversal from a net loss of $43.77 million in Q1 2025. Gross margins are exceptionally high at 99.06% for the quarter, which is typical for a commercial-stage biotech with a proprietary drug, and operating margins stood at a healthy 44.08%. This shift from deep losses to substantial profitability in a single year is the core of the current investment debate. The balance sheet and cash flow position appear strong based on the latest quarterly data. The company generated free cash flow of $48.65 million in Q4 2025 and has a very solid current ratio of 5.80, indicating ample liquidity. The debt-to-equity ratio is minimal at 0.006, suggesting the company is not leveraged and funded its operations and growth through equity. The return on equity (ROE) for the quarter was 9.63%, a positive signal of capital efficiency following the commercial launch.
Quarterly Revenue
$91730000.0B
2025-12
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
+0.99%
Latest Quarter
Free Cash Flow
$46903000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SLNO Overvalued?
Given the company's positive net income of $43.36 million in the latest quarter, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing twelve-month PE ratio is exceptionally high at 117.86x, while the forward PE is negative at -17.40x; this stark divergence between a high trailing multiple and a negative forward multiple is highly unusual and likely reflects analyst expectations for significant earnings volatility or a reversion to losses in the coming year, casting doubt on the sustainability of recent profitability. A direct peer comparison using industry average multiples is not possible as the provided valuation data lacks industry benchmarks. However, the stock's own sales-based multiples are elevated, with a Price-to-Sales (PS) ratio of 12.93 and an EV-to-Sales of 9.38, which may reflect a premium for its rare disease market position and high gross margins, but also incorporates significant risk given the ongoing legal overhang. Historically, the stock's valuation has been extremely volatile, mirroring its clinical and commercial milestones. The current trailing PE of 117.86x is significantly above its own historical PE of 14.20x recorded at the end of Q4 2025, just a few months prior. This suggests the market is currently applying a much higher multiple to a lower earnings base, which could indicate either renewed optimism or, more likely, a distortion caused by the precipitous stock price decline compressing the market cap while quarterly earnings remained strong.
PE
117.9x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -225x~35x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
84.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are centered on extreme earnings volatility and single-product dependency. The company's valuation reflects this, with a trailing PE of 117.86x and a negative forward PE of -17.40x, signaling analyst expectations for earnings to collapse. All revenue ($91.73M in Q4) and future growth are tied to DCCR, making the company highly vulnerable to any safety, efficacy, or reimbursement challenges. While current margins (47.27% net) and cash flow ($48.65M FCF in Q4) are strong, they are entirely contingent on uninterrupted commercial success for this one drug.
Market & Competitive Risks are dominated by the securities fraud lawsuit, which has already triggered a 66.04% maximum drawdown. The stock's beta of -2.805 indicates it is a highly speculative, anti-market instrument, prone to severe downdrafts during market stress or company-specific bad news. Valuation compression is a major risk, as the current PS ratio of 12.93 and EV/Sales of 9.38 are high and could contract sharply if growth decelerates or legal risks intensify. The lack of a broad analyst consensus (only 6 analysts) contributes to inefficient price discovery and heightened volatility.
Worst-Case Scenario involves the securities fraud lawsuit resulting in a material adverse finding, leading to a loss of physician/patient confidence in DCCR, collapsing sales, and potential regulatory scrutiny. This could trigger a cascade of analyst downgrades, investor flight, and a liquidity crisis despite the strong current balance sheet. The realistic downside could see the stock retesting and breaking its 52-week low of $29.43, representing a -25% decline from the current $39.49. In a severe scenario where commercialization halts, the stock could fall towards its cash value, implying a potential loss exceeding 50%.
FAQ
The key risks are: 1) Legal & Existential Risk: The securities fraud lawsuit directly challenges the commercial narrative of its sole product, DCCR. An adverse outcome could cripple the business. 2) Single-Product Dependency: 100% of revenue comes from DCCR, creating extreme concentration risk. 3) Extreme Volatility & Sentiment Risk: The stock has a beta of -2.805 and has experienced a 66.04% maximum drawdown, making it highly unpredictable. 4) Earnings Sustainability Risk: The negative forward PE of -17.40x indicates analysts expect profitability to be fleeting, creating risk of sharp multiple contraction if earnings decline.
The 12-month forecast for SLNO is highly bifurcated, with a 50% probability base case target range of $35-$55, a 25% probability bull case of $70-$90, and a 25% probability bear case of $25-$35. The base case is most likely, assuming the legal overhang persists but commercial execution remains solid, leading to volatile, range-bound trading. The forecast hinges almost entirely on the resolution of the securities lawsuit and the subsequent quarterly revenue trends. The wide dispersion in targets reflects the extreme uncertainty and binary nature of the current investment debate.
SLNO's valuation is distorted and difficult to assess, trading at a trailing PE of 117.86x based on strong recent earnings, but at a negative forward PE of -17.40x reflecting analyst pessimism. Its Price-to-Sales ratio of 12.93 is elevated, typical for a commercial biotech but incorporating high risk. Compared to its own historical PE of 14.20x from just a few months prior, the current multiple is vastly higher, suggesting the market is applying a premium to a lower earnings base due to the stock price collapse. The valuation is not clearly overvalued or undervalued; it is fairly valued for the extreme uncertainty, pricing in both high growth potential and catastrophic legal risk.
SLNO is not a good stock to buy for most investors at this time due to the extreme binary risk posed by the ongoing securities fraud lawsuit. While the company has demonstrated impressive fundamental performance with Q4 2025 revenue of $91.73M and net income of $43.36M, the stock's 46.4% annual decline, -2.805 beta, and proximity to its 52-week low reflect severe legal and sentiment headwinds. It could be a speculative buy for risk-tolerant investors who believe the lawsuit will be resolved favorably and that the current price near $39.49 discounts the worst-case scenario. For others, it is a 'Hold' or 'Avoid' until the legal cloud clears.
SLNO is unsuitable for traditional long-term investment due to its unresolved existential legal risk and extreme volatility (beta -2.805). It does not pay a dividend and its earnings visibility is poor, as indicated by the negative forward PE. It may be suitable only for very short-term, tactical trading by sophisticated investors who can closely monitor legal developments and quarterly earnings. Given the need for clarity on the lawsuit, any investment should be considered with a horizon of 3-6 months to reassess the thesis post-catalyst. A minimum holding period cannot be responsibly recommended until the legal overhang is resolved.